Immunohistochemical Studies of Cd150 Expression in Some Human Tumors

Received: June 24, 2003. *Correspondence: Fax: 380(44)-2581656; E-mail: [email protected] Abbreviations used: ABC-DLBCL — diffuse large B-cell lymphoma with activated B cell phenotype; BCR — B cell receptor; BL — Burkitt’s lymphoma; DLBCL — diffuse large B-cell lymphoma; GC — germinal center; GC-DLBCL — diffuse large B-cell lymphoma with germinal center phenotype; HL — Hodgkin’s lymphoma; HRS — Hodgkin/Reed — Sternberg cells; LPL — lymphoplasmacytic lymphoma; MCL — mantle cell lymphoma; NHL — non-Hodgkin’s lymphoma; SH2D1A — SH2 domain protein 1A; SLL — small lymphocytic lymphoma of B-cell origin; XLP — X-linked lymphoproliferative syndrome. CD150 (IPO-3/SLAM) is a cell surface receptor that belongs to novel CD2/CD150 subfamily of Ig superfamily of cell surface receptors. Expression of this receptor was found on activated hematopoietic cells: T and B lymphocytes, monocytes and dendritic cells. High expression of CD150 was also revealed on thymocytes. CD150 was shown to play a dual role in regulation of lymphocyte fate, and as the B cell receptor (BCR), CD40 or CD95/Fas has a potential to transmit positive or negative signals [1, 2]. CD150 cytoplasmic tail possess specific signaling motif TxYxxI/V that serves a IMMUNOHISTOCHEMICAL STUDIES OF CD150 EXPRESSION IN SOME HUMAN TUMORS